Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5568957 | 0.85 | ALDH1A1 (0.44) | HPGDTSHRALDH1A1NPSR1POLB | |
| SCHEMBL4816249 | 0.84 | HPGD (0.57) | HPGDALDH1A1NPSR1POLBKDM4E | |
| SCHEMBL7931144 | 0.83 | HTT (0.54) | HPGDALDH1A1NPSR1POLBKDM4E | |
| SCHEMBL29426981 | 0.83 | HPGD (0.49) | HPGDTSHRALDH1A1POLBKDM4E | |
| SCHEMBL18758854 | 0.83 | HPGD (0.49) | HPGDTSHRALDH1A1POLBKDM4E | |
| SCHEMBL31096231 | 0.83 | TSHR (0.56) | HPGDTSHRALDH1A1POLBKDM4E | |
| SCHEMBL182753 | 0.83 | TSHR (0.56) | HPGDTSHRALDH1A1POLBKDM4E | |
| SCHEMBL12121221 | 0.82 | KDM4E (0.52) | HPGDALDH1A1NPSR1POLBKDM4E | |
| SCHEMBL525666 | 0.82 | ALDH1A1 (0.48) | HPGDTSHRALDH1A1NPSR1POLB | |
| SCHEMBL13985948 | 0.82 | ALDH1A1 (0.55) | HPGDTSHRALDH1A1NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11666557-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20200138790-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2020-05-07 | — | — | US | disclosed |
| US-10568871-B2 | Triazolone compounds and uses thereof | TEMPEST THERAPEUTICS, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| EP-2935228-B9 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2017-08-24 | — | — | US | disclosed |
| EP-2935228-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-9676754-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| EP-2822931-B1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | INCEPTION 2 INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9505728-B2 | Triazolone compounds and uses thereof | INCEPTION 2, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-7473790-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473783-B2 | Bicyclic pyrazolo protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| WO-2008063300-A2 | BORONIC ACIDS AND ESTERS AS INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11666557-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | HPGD 2329/4885TSHR 1480/4885ALDH1A1 589/4885 |
| US-20240041837-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | HPGD 2329/4885TSHR 1480/4885ALDH1A1 589/4885 |
| US-10568871-B2 | Triazolone compounds and uses thereof | PPARA, PPARG, PPARD | HPGD 2329/4885TSHR 1480/4885ALDH1A1 589/4885 |
| US-20200138790-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | HPGD 2329/4885TSHR 1480/4885ALDH1A1 589/4885 |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | HPGD 3792/4885TSHR 4566/4885ALDH1A1 1601/4885 |
| US-20170239223-A1 | TRIAZOLONE COMPOUNDS AND USES THEREOF | PPARA, PPARG, PPARD | HPGD 2329/4885TSHR 1480/4885ALDH1A1 589/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | HPGD 1904/4885TSHR 3884/4885ALDH1A1 322/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | HPGD 1904/4885TSHR 3884/4885ALDH1A1 322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.